Our advisory panel

Find out about the Cell and Gene Therapy Catapult advisory panel

Our advisory panel consists of academic and industry leaders that have expertise across science, medicine and technologies, and all come from a range of highly respected European academic organisations and the international pharmaceutical and biotechnology industry. We hope to expand in the near future to invite members from the investment community due to increased interest from this group.

Outcomes and recommendations from the panel will feed into our strategy, positioning and planning to help ensure the continued growth of our organisation and the success of the cell and gene therapy industry.

Michael Hunt


Michael joined ReNeuron in 2001. Between 2005 and 2014 he served as its CEO, leading the business through its early development to its current position as one of the global, clinical-stage leaders in the regenerative medicine field. Prior to ReNeuron, he spent six years at Biocompatibles International plc (sold to BTG plc) where he held a number of senior financial and general management positions.

Michael is a founding member and co-chair of the European Alliance for Advanced Therapies and sits on the BioIndustry Association’s Cell Therapy and Regenerative Medicine Advisory Committee and its Finance and Tax Advisory Committee. He currently sits as an industry member on the UK Department of Health’s Regenerative Medicine Expert Group. He read economics at University College London and qualified as a chartered accountant with Ernst & Young.

Dr Mark Zimmerman

J&J Innovation

Mark received his bachelors in biology from Syracuse University and his masters and doctorate in biomedical engineering from Rutgers University. 

Mark joined Johnson and Johnson in 1997 as a principal scientist/group leader where he was responsible for managing a tissue-engineering program. Mark transitioned into regenerative medicine projects related to wound healing, vascular biology, and diabetes. Mark was appointed Executive Director of a Lifescan incubator, BetaLogics, in July 2002.

Mark is a fellow in the American Institute of Mechanical and Biomedical Engineers, a member of numerous societies (Tissue Engineering Society, International Society for Stem Cell Research, the International Society for Cell Therapy, the American Diabetes Association, the American Society of Mechanical Engineers, the Biomaterials Society), and he sits on the External Advisory Council of the NIH Institute for Regenerative Medicine. Mark has authored 44 peer-reviewed publications, 10 book chapters, 136 abstracts and is an inventor on 24 patents.

Dr Edward Hodgkin

Syncona Partners

Edward is a Partner of Syncona Partners LLP. Previously, he was Chief Executive Officer of Biotica Technology Ltd. Prior to joining Biotica in 2007, he spent 12 years in the US, serving as President and Chief Business Officer of BrainCells, Inc. (San Diego, CA) and Vice President, Business Development and Marketing at Tripos Inc. (St. Louis, MO).

Edward has broad deal-making experience, including licensing, strategic alliances, company formation, equity financing and dispute resolution. His early career was spent in scientific and management roles at Wyeth-Ayerst, Inc. (Princeton, NJ) and British Biotech Ltd. (Oxford). Ed holds an MA and DPhil in Chemistry from Oxford University.

Dr Regina Fritsche-Danielson


Regina is Senior Director and Head of Heart Failure Bioscience at AstaZeneca R&D, in Sweden. She has a background in cardiovascular physiology and pharmacology and has over 13 years’ experience in pharma.

Regina is Strategy area lead for cardiac regeneration/heart failure and Project Leader within cardiovascular diseases and in new modalities (modRNA).

Professor Paul Fairchild

University of Oxford

Paul is an Associate Professor and Lecturer in pre-clinical medicine within the Sir William Dunn School of Pathology and a Fellow of Trinity College. He began his research career in Oxford, where he studied for a doctorate in the Nuffield Department of Surgical Sciences.

After spending five years as a Post-doctoral Fellow investigating the aetiology of autoimmune disease in the Department of Pathology, at Cambridge University, Paul returned to Oxford.  In 2008, he founded the Oxford Stem Cell Institute (OSCI), for which he continues to serve as Co-Director. As a highly interdisciplinary research institute, the OSCI focuses on exploiting the properties of stem cells for the treatment of some of most intractable chronic and degenerative diseases. It is within this context that Paul continues to apply his background in transplantation immunology, to investigate the nature of the immune response to tissues differentiated from pluripotent stem cells and to develop approaches to the induction and maintenance of immunological tolerance.

Professor Chris Mason

University College London

Chris is Professor of Regenerative Medicine Bioprocessing in the Advanced Centre for Biochemical Engineering, University College London. He has a multidisciplinary track record spanning discovery, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and business.

He holds a clinical sciences degree from Imperial College London, an MD from the United Medical and Dental Schools of Guy’s and St. Thomas’s Hospitals (now King’s College London) and a PhD in tissue-engineering bioprocessing from University College London. Current appointments include; Senior Editor of “Regenerative Medicine” journal, Co-founder and CEO of the London Regenerative Medicine Network, and Co-Chair of the Alliance for Regenerative Medicine Cell Therapy Section.

Chris is on many national and international committees, working groups and initiatives related to the academic, clinical and commercial advancement of cell therapy is a general spokesperson for the sector including frequent newspaper, radio and TV interviews.

Professor Adrian Thrasher

University College London

Adrian is Professor of Paediatric Immunology and Wellcome Trust Principal Research Fellow at the UCL Great Ormond Street Institute of Child Health, and Honorary Consultant Paediatric Immunologist at Great Ormond Street Hospital for Children NHS Foundation Trust.

He is the Programme Head of Infection, Immunity and Inflammation at UCL GOS ICH and has a long standing research and clinical interest in development and application of gene therapy. He is Director of the Clinical Gene Therapy Programme, and Theme Leader of the Gene Stem and Cellular Therapies theme of the Biomedical Research Centre, at UCL GOS ICH/GOSH.  Adrian is PI on several clinical trials for immunodeficiency and is Director of the clinical gene therapy GMP facility, managing a team of trial coordinators, clinical scientists, and quality systems personnel.

Professor Graham Lord

University of Manchester

Professor Graham Lord was appointed as Vice-President and Dean of the Faculty of Biology, Medicine and Health at the University of Manchester in 2019. He is also an Honorary Consultant Nephrologist at Manchester NHS Foundation Trust. He was previously the Professor of Medicine and Head of the Department of Experimental Immunobiology at King’s College London and the Director of the NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust from 2012-2019.

He qualified in medicine from Cambridge and trained at the Hammersmith Hospital and Imperial College as an academic renal physician. Following postdoctoral training at Harvard University, he moved back to the UK in 2006 and established a research group based on the regulation of lymphocyte gene expression. He has clinical interests in multi-organ transplantation and the genetics of allograft loss.


Professor Petra Reinke

Charité - Universitätsmedizin Berlin

Petra is a Nephrologist and Clinical Scientist within the following scientific topics: transplantation medicine, development of new diagnostic and therapeutic approaches in transplantation.

Petra has wide experience in managing and coordination of international consortia. She is Project coordinator for the EU founded FP7 consortium “BIO-DrIM” collaborative project (2012-2017) and was Steering committee member and workpackage leader of the EU founded FP7 consortium “ONE- Study” (2010-2015), Steering committee member and work-package leader of the EU founded FP6 consortium “RISET”, 2005-2010; Co-PI for a project founded by the Immune Tolerance Network (ITN) (2000-2003) and Co-Investigator ROTF grant (1997-2000).

She is Medical Director Nephrology and Transplantation and Head of the “Kidney Transplant Outpatient Clinic” at the Dept. Nephrology CVK; Head of research area “immune system”, Head of the GMP-Facility developing new Tcell based therapeutic strategies for SOT patients in phase I/IIa and Steering Committee Member of the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), of the DFG-sponsored Berlin-Brandenburg School for Regenerative Therapies (BSRT) and of the Berlin Institute of Health (BIH) Stem Cell Center.

She has published more than 300 articles in different transplant research areas.

  • Find your perfect job in the Cell and Gene Therapy sector 🤩 We have a whole range of exciting new vacancies over o… https://t.co/WTBfrR00s4 1 day 3 hours ago

Discover who we are